Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders

The shareholders approved the proposal to reappoint Deborah Jorn, MBA, the Vice-Chair of the Board of Directors, as Non-Executive Director for a period of two years (agenda item 3.b). The shareholders approved the proposal to reappointDeborah Jorn, MBA, the Vice-Chair of the Board of Directors, as Non-Executive Director for a period of two years (agenda item 3.b). The proposal to grant specific authorization for the issuance of shares, or rights to acquire shares, to finance mergers,...

The shareholders approved the proposal to reappoint Deborah Jorn, MBA, the Vice-Chair of the Board of Directors, as Non-Executive Director for a period of two years (agenda item 3.b).

The proposal to grant specific authorization for the issuance of shares, or rights to acquire shares, to finance mergers, acquisitions or strategic alliances (agenda item 7.b) was withdrawn at the start of the AGM, as the quorum requirement was not met for the proposed authorization to exclude the pre-emptive rights of existing shareholders.

The proposal for authorization to issue shares, or rights to acquire shares, for general financing purposes (agenda item 7.a) was approved by the shareholders.  

A recording of the webcast, presentation slides from today's AGM, and more details regarding agenda items are available on the Company's website in the Investor Relations section.

About Pharming Group N.V.

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further public information, contact:

Pharming Group, Leiden, The Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager
E: investor@pharming.com 

FTI Consulting, London, UK
Victoria Foster Mitchell/ Alex Shaw/ Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens 
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

View original content:https://www.prnewswire.co.uk/news-releases/pharming-group-reports-on-results-of-the-2023-annual-general-meeting-of-shareholders-301827463.html